NEW YORK (GenomeWeb News) – Sequenom today lowered its revenue forecast for 2008 by 5 percent compared to earlier forecasts, citing softer than expected sales in the US market for its first quarter.
The San Diego-based firm revised its 2008 guidance downward to a range between $50 million and $53 million from previous guidance of between $53 million and $56 million. Its expected net loss, however, remained unchanged from previous estimates of $30 million to $33 million for the year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.